The synergistic effect of the CDK1 inhibitor and BETi observed in our studies therefore provides the rationale for exploring aberrant CDK1 activation in cancer cells as a therapeutic target to overcome tumor BETi resistance and improve treatments for a diverse array of BRD4-associated cancers. The gene discussed is CDK1; the disease is neoplasm.